-
Study aim
-
Comparison of ivf outcomes in two regimens of ovulation stimulation, conventional (antagonist) and Stop GnRH-agonist/GnRH-antagonist in poor ovarian responses
-
Design
-
A clinical trial with a control group, with parallel groups, double-blind, non-randomized on 60 patients
-
Settings and conduct
-
In antagonist protocol, from the 2nd-3rd day of the mens, Clomiphene started, one tablet every 12 hours, and Elnova, which is a long-acting gonadotropin, is taken at a dose of 150 and from the 6th day of gonadotropin, While in the stop protocol, the gnrh agonist starts in the mid-luteal phase (previous cycle) and stops with the onset of menstruation and after confirmation of ovarian inhibition in TVS. Then, from the 2nd-3rd day of the clomiphene cycle, one pill every 12 hours is started, and he takes an ampoule of Elnova with a dose of 150. In both groups, after 5 days, ultrasound was performed when the leading follicle reached 13-14 mm in size, the antagonist was started and when at least 2-3 follicles above 18 that the final trigger is done and opu is done 34-40 hours later.
-
Participants/Inclusion and exclusion criteria
-
POR patients (age (≤40 years) or any other risk factor for POR such as endometriosis and ovarian surgery, autoimmune diseases and genetic problems 2: previous presence of ≤3 eggs with the usual stimulation protocol 3: abnormality of ovarian reserve tests
-
Intervention groups
-
Use of the new Stop GnRH-agonist/GnRH-antagonist ovulation stimulation protocol in patients with poor response compared to the usual antagonist regimen
-
Main outcome variables
-
primary outcomes of the number of follicles above 16 mm, follicle synchrony, number and quality of oocytes and the secondary outcomes of the number and quality of embryos - total dose of gonadotropins - and final cost